As of March 6, 2019, thirty participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United States and Canada. The purpose of this study is to provide the final training and provide supervision for our co-therapy teams as they each work with one subject with PTSD using the same treatment approach to be used in Phase 3. Study sites are now enrolling and all sites are fully enrolled. We are currently developing long-term follow-up protocol for this multi-site open-label Phase 2 study, which will assess symptoms of PTSD in participants 12 months after completing treatment.